13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002106939
Total reported value
$187.9M
$187.9M
79 檔
60.1%
During the Q1 2026 filing period, PSP Research LLC (CIK: 0002106939) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $187.9M across 79 reported positions.
In Q1 2026, PSP Research LLC adopted a defensive or profit-taking posture, trimming 42 positions and completely liquidating 27 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 49.86% | -12.35% | — | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 25.75% | +22.26% | — | |
| 3 | SERA | Sera Prognostics Inc-a | Stock-Other | 3.44% | -3.44% | EXIT | |
| 4 | DFTX | Definium Therapeutics Inc | Stock-Other | 0.47% | -0.22% | — | |
| 5 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.43% | -0.43% | EXIT | |
| 6 | ASND | Ascendis Pharma A/S | Stock-Other | 0.40% | -0.40% | EXIT | |
| 7 | PHVS | Pharvaris N.V. | Stock-Other | 0.40% | -0.12% | -2.49% | |
| 8 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.39% | -0.39% | EXIT | |
| 9 | RPRX | Royalty Pharma plc | Stock-Healthcare | 0.37% | -0.04% | -20.44% | |
| 10 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.37% | -0.13% | -0.76% | |
| 11 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.37% | -0.08% | — | |
| 12 | EXEL | Exelixis Inc | Stock-Healthcare | 0.36% | -0.13% | — | |
| 13 | IRON | Disc Medicine Inc | Stock-Other | 0.36% | -0.05% | — | |
| 14 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.36% | -0.07% | — | |
| 15 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 0.36% | -0.36% | EXIT | |
| 16 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.36% | -0.09% | +3.05% | |
| 17 | INCY | Incyte CORP | Stock-Healthcare | 0.35% | -0.03% | -0.93% | |
| 18 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.35% | -0.12% | +7.38% | |
| 19 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.35% | -0.14% | +1.94% | |
| 20 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.34% | -0.11% | +11.15% | |
| 21 | PRAX | Praxis Precision Medicines I | Stock-Other | 0.34% | -0.34% | EXIT | |
| 22 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.34% | -0.21% | — | |
| 23 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.34% | -0.12% | +0.54% | |
| 24 | ARDX | Ardelyx Inc | Stock-Other | 0.34% | -0.18% | — | |
| 25 | IMVT | Immunovant Inc | Stock-Other | 0.34% | -0.07% | -5.44% | |
| 26 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.33% | -0.01% | +1.75% | |
| 27 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.33% | -0.10% | -19.08% | |
| 28 | INBX | Inhibrx Biosciences Inc | Stock-Other | 0.33% | -0.33% | EXIT | |
| 29 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.33% | -0.06% | +5.26% | |
| 30 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.33% | -0.03% | — | |
| 31 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.33% | -0.17% | -27.05% | |
| 32 | COGT | Cogent Biosciences Inc | Stock-Other | 0.33% | -0.08% | -9.32% | |
| 33 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.33% | -0.03% | — | |
| 34 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.32% | -0.06% | +4.97% | |
| 35 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 0.32% | -0.17% | -0.84% | |
| 36 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.32% | -0.20% | -15.97% | |
| 37 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.31% | +0.01% | -0.05% | |
| 38 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 0.31% | -0.04% | -11.64% | |
| 39 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.31% | -0.04% | — | |
| 40 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.31% | — | -20.03% | |
| 41 | IMNM | Immunome Inc | Stock-Other | 0.31% | -0.11% | -20.78% | |
| 42 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.31% | -0.14% | -28.88% | |
| 43 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.31% | -0.02% | -27.00% | |
| 44 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.30% | -0.17% | -60.71% | |
| 45 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.29% | -0.03% | -36.17% | |
| 46 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 0.29% | -0.03% | -14.85% | |
| 47 | VERA | Vera Therapeutics Inc | Stock-Other | 0.28% | -0.12% | +0.04% | |
| 48 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.28% | -0.09% | — | |
| 49 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.28% | -0.06% | -2.79% | |
| 50 | CMPS | Compass Pathways PLC | Stock-Other | 0.28% | -0.14% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | KYMR | Kymera Therapeutics Inc | -0.1% | -0.76% | Trim |
| 2 | TYRA | Tyra Biosciences Inc | -0.1% | -26.78% | Trim |
| 3 | CYTK | Cytokinetics Inc | -0.1% | -0.16% | Trim |
| 4 | ASND | Ascendis Pharma A/S | -0.1% | -3.06% | Trim |
| 5 | COGT | Cogent Biosciences Inc | -0.1% | -9.32% | Trim |
| 6 | VKTX | Viking Therapeutics Inc | -0.1% | +1.94% | Add |
| 7 | NBIX | Neurocrine Biosciences Inc | -0.1% | +3.05% | Add |
| 8 | HALO | Halozyme Therapeutics Inc | -0.1% | — | Unchanged |
| 9 | EXEL | Exelixis Inc | -0.1% | — | Unchanged |
| 10 | RPRX | Royalty Pharma plc | -0.1% | -20.44% | Trim |
| 11 | PHVS | Pharvaris N.V. | -0.1% | -2.49% | Trim |
| 12 | DYN | Dyne Therapeutics Inc | -0.1% | -7.13% | Trim |
| 13 | IMVT | Immunovant Inc | -0.1% | -5.44% | Trim |
| 14 | INBX | Inhibrx Biosciences Inc | -0.1% | +8.42% | Add |
| 15 | INCY | Incyte CORP | -0.1% | -0.93% | Trim |
| 16 | IONS | Ionis Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 17 | SNDX | Syndax Pharmaceuticals Inc | -0.1% | -19.08% | Trim |
| 18 | CRSP | CRISPR Therapeutics AG | -0.1% | -0.84% | Trim |
| 19 | IMCR | Immunocore Holdings Plc-adr | -0.1% | +4.97% | Add |
| 20 | NAMS | NewAmsterdam Pharma Company N.V. | -0.1% | +0.54% | Add |
| 21 | TARS | Tarsus Pharmaceuticals Inc | -0.1% | +7.38% | Add |
| 22 | ALNY | Alnylam Pharmaceuticals Inc | -0.1% | +11.15% | Add |
| 23 | ARGX | Argenx Se - Adr | -0.1% | +1.75% | Add |
| 24 | MIRM | Mirum Pharmaceuticals Inc | -0.1% | -27.05% | Trim |
| 25 | TGTX | Tg Therapeutics Inc | -0.2% | -27.00% | Trim |
| 26 | RAPP | Rapport Therapeutics Inc | -0.2% | -20.03% | Trim |
| 27 | KNSA | Kiniksa Pharmaceuticals International, plc | -0.2% | -28.88% | Trim |
| 28 | ACAD | Acadia Pharmaceuticals Inc | -0.2% | — | Unchanged |
| 29 | ARQT | Arcutis Biotherapeutics Inc | -0.2% | +5.26% | Add |
| 30 | IMNM | Immunome Inc | -0.2% | -20.78% | Trim |
| 31 | DNTH | Dianthus Therapeutics Inc | -0.2% | -60.71% | Trim |
| 32 | VERA | Vera Therapeutics Inc | -0.2% | +0.04% | Add |
| 33 | BBIO | Bridgebio Pharma Inc | -0.2% | -15.97% | Trim |
| 34 | AUPH | Aurinia Pharmaceuticals Inc | -0.2% | -11.64% | Trim |
| 35 | PRAX | Praxis Precision Medicines I | -0.2% | -24.32% | Trim |
| 36 | NRIX | Nurix Therapeutics Inc | -0.2% | -0.05% | Trim |
| 37 | STOK | Stoke Therapeutics Inc | -0.2% | -27.80% | Trim |
| 38 | CRNX | Crinetics Pharmaceuticals In | -0.2% | -2.79% | Trim |
| 39 | PTCT | Ptc Therapeutics Inc | -0.2% | -14.85% | Trim |
| 40 | CLDX | Celldex Therapeutics Inc | -0.2% | -36.17% | Trim |
| 41 | HRMY | Harmony Biosciences Holdings | -0.2% | — | Unchanged |
| 42 | KOD | Kodiak Sciences Inc | -0.2% | -48.50% | Trim |
| 43 | MDGL | Madrigal Pharmaceuticals Inc | -0.2% | -32.74% | Trim |
| 44 | SUPN | Supernus Pharmaceuticals Inc | -0.3% | -44.23% | Trim |
| 45 | PTGX | Protagonist Therapeutics Inc | -0.3% | -50.99% | Trim |
| 46 | SYRE | Spyre Therapeutics Inc | -0.3% | -67.43% | Trim |
| 47 | ZYME | Zymeworks Inc | -0.3% | -50.77% | Trim |
| 48 | XENE | Xenon Pharmaceuticals Inc | -0.3% | -64.03% | Trim |
| 49 | CELC | Celcuity Inc | -0.3% | -61.86% | Trim |
| 50 | OLMA | Olema Pharmaceuticals Inc | -0.3% | -47.54% | Trim |
According to official SEC Form 13F filings, PSP Research LLC reported a total U.S. public equity portfolio value of $187.9M across 79 disclosed positions in Q1 2026.
During Q1 2026, PSP Research LLC's top holdings by market value included SGOV (49.9%)、XBI (25.8%)、SERA (3.4%). The largest single position, SGOV, represented 49.9% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SGOV, XBI, SERA) accounted for 60.1% of total reported equity market value during Q1 2026.
Top New Position Initiated
XBI
市值: $36.4M
Top Position Liquidated / Trimmed
TVTX
前期市值: $583.5K
In Q1 2026, PSP Research LLC made 100 total portfolio adjustments, initiating 21 new buys, adding to 10 positions, trimming 42 holdings, and fully liquidating 27 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.